Abstract:Context: Dilated cardiomyopathy (DCM) is the terminal manifestation of many heart diseases, and atrial fibrillation (AF) is the most common type of arrhythmia in DCM. The mutual influence of DCM and AF can ultimately lead to a poor prognosis for patients. Objective: The study intended to investigate the risk factors for DCM complicated with AF as well as the expression and clinical value of miR-499 and IL-1β, to provide more research targets for controlling the risk of AF in clinical practice. Design: The research team conducted a retrospective, observational, case-control study. Setting: The study took place at Huai'an First People's Hospital. Participants: Participants were 79 patients with DCM who had been admitted to the hospital between January 2018 and January 2023. Groups: The study included two groups: (1) 31 participants with atrial fibrillation (AF), the AF group and (2) 48 participants without AF, the non-AF group. Outcome measures: The research team: (1) examined the baseline characteristics of the two groups and compared the groups using single factor analysis; (2) compared the group's serum indicators and echocardiographic parameters; (3) evaluated the expression and potential relationship of microRNA (miR-499) and interleukin-1 beta (IL-1β) to AF, using reverse transcription-polymerase chain reaction (RT-PCR) and Pearson, and compared the group's expressions of miR-499 and IL-1β; and (4) analyzed the potential relationship between participants' characteristics and the occurrence of AF, using binary logistic regression. Results: Compared to the non-AF group, the AF group's: (1) age (P = .000) and number of participants with a high pulmonary artery pressure (P = .004) were significantly greater; (2) LVEF was significantly lower (P = .030) and LVESD (P = .000), LAD (P = .018), uric acid (P = .000), and BNP (P = .000) were significantly higher; and (3) serum miR-499 (P = .020) and IL-1β (P = .000) were significantly higher. Also, a significant positive correlation existed between miR-499 (P = .019) and IL-1β (P = .022) and DCM with AF. In addition, the AF group's age (P = .001), disease duration (P = .032), serum triglyceride levels (P = .036), uric acid value (P = .001), left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD), left atrial anteroposterior diameter, LAD, pulmonary hypertension were significant independent risk factors DCM with AF. Conclusions: A close relationship exists between the abnormal expression of serum miR-499 and IL-1β and DCM complicated with AF, which will be of great importance in future research. In addition, the data of patients with DCM are related to the occurrence and development of AF, and clinicians should actively perform early drug interventions to reduce myocardial remodeling, so as to reduce the incidence of AF.

Effect of Interferon on Autoimmune and Virus in Dilated Cardiomyopathy

Effect of Interferon on Cardiac Function in Dilated Cardiomyopathy

A Meta-analysis on curative effect of Shengmai Injection on dilated cardiomyopathy

[Effect of Intravenous Immunoglobulin and Vitamin C on Progression of Experimental Autoimmune Myocarditis in Mice].

Peripheral Endothelial Function May Predict the Effectiveness of Beta-Blocker Therapy in Patients with Idiopathic Dilated Cardiomyopathy.

Transcriptome Analysis Uncovers the Autophagy‐mediated Regulatory Patterns of the Immune Microenvironment in Dilated Cardiomyopathy

Advanced Interfere Treatment of Diabetic Cardiomyopathy Rats by Afgf-Loaded Heparin-Modified Microbubbles and UTMD Technique

Immune cells and related cytokines in dilated cardiomyopathy

Dilated cardiomyopathy and chronic cardiac inflammation: Pathogenesis, diagnosis and therapy

Effect of fluvastatin on cytokines and cardiac function in patients with idiopathic dilated cardiomyopathy

Expression and Potential Significance of miR-499 and IL-1β in Serum of Dilated Cardiomyopathy Patients with Atrial Fibrillation

Amelioration of Heart Function by Intracoronary Autologous Bone Marrow Mononuclear Cells Transplantation in Idiopathic Dilated Cardiomyopathy: a Clinical Study

Expression and Significance of Coxsackie-Adenovirus Receptor in Myocardia With Dilated Cardiomyopathy

Autoantibodies and Anti-Interferon Antibody in Patients with Chronic Viral Hepatitis and Its Clinical Significance: a Preliminary Investigation.

Expression Profile of Inflammation Response Genes and Potential Regulatory Mechanisms in Dilated Cardiomyopathy

Role of Coxsackievirus B3-Induced Immune Responses in the Transition from Myocarditis to Dilated Cardiomyopathy and Heart Failure

Effects of interferon-alpha therapy on cardiac function in patients with chronic hepatitis B infection

Identification of the Key Genes of Immune Infiltration in Dilated Cardiomyopathy.

The Molecular Role of Immune Cells in Dilated Cardiomyopathy

Impact of inflammation and anti-inflammatory modalities on diabetic cardiomyopathy healing: From fundamental research to therapy

Observation on Collaborative Treatment of Dilated Cardiomyopathy